Moneycontrol PRO
HomeNewsPharmaceutical companies

Pharmaceutical Companies

Jump to
  • Pharma companies with over Rs 250 cr turnover have to adopt Good Manufacturing Practices within 6 months: Mandaviya

    India is a major exporter of medicines to LMIC (Low and Middle-Income Countries) which require WHO GMP certification. There are around 2,000 units in the MSME category in the country having WHO GMP certification.

  • Easing margin pressures, uptick in US sales saving grace for pharma firms in Q3

    Easing margin pressures, uptick in US sales saving grace for pharma firms in Q3

    Despite moderation in margin pressure, a rise in input costs for some medications can derail pharma sector's recovery, say analysts

  • Motilal Oswal downgrades Lupin to 'sell' after slump in Q3 results

    Motilal Oswal downgrades Lupin to 'sell' after slump in Q3 results

    "We value LPC (Lupin) at 22x 12M forward earnings to arrive at a price target of Rs 610," Motilal Oswal said. The pharma major's shares closed at Rs 737 apiece at the end of the last trading session.

  • Startups that make healthcare more affordable, accessible will succeed: Ex-US health official

    Startups that make healthcare more affordable, accessible will succeed: Ex-US health official

    Many Indian digital healthcare startups are focussed on accessibility and affordability, said David Shulkin, former US secretary of veterans affairs, who currently advises Indegene on using digital tools to help life sciences companies.

  • Doctor-Pharma Nexus Part II: What drives drug prescription in India?

    Doctor-Pharma Nexus Part II: What drives drug prescription in India?

    If doctors are concerned about the quality of generic drugs and hesitate to prescribe them, how do they decide which medicines patients should take?

  • Pharma-Doctor Nexus Part I: Why rules, Code for doctors, drugmakers have failed to curb unethical practices

    Pharma-Doctor Nexus Part I: Why rules, Code for doctors, drugmakers have failed to curb unethical practices

    The Medical Council of India's (now Medical Commission of India's) rules for doctors and the Uniform Code of Pharmaceutical Marketing Practices have elaborate guidelines to curb such practices, but with no real statutory backing they remain on paper even as the patients suffer. 

  • Move to open opium market to private players could take Rs 1,000 crore business to new highs

    Move to open opium market to private players could take Rs 1,000 crore business to new highs

    Moneycontrol takes you into India’s poppy fields to explain what opium derivatives are used for and gives you a whiff of this narcotic’s potent economic potential.

  • US price erosion triggers strategy rejig at Indian pharma

    US price erosion triggers strategy rejig at Indian pharma

    Drug suppliers rethink their investment strategy as continuous price erosion hurts profitability and returns from the US market

  • Budget 2022 stops pharma companies from claiming tax cuts on freebies to doctors

    Budget 2022 stops pharma companies from claiming tax cuts on freebies to doctors

    Despite a code by the Medical Council of India that prohibits gifts from pharma companies to doctors that came into effect over a decade back, the practice has continued as there is no law barring the firms from offering the largesse to doctors

  • Trade names of drugs may soon be regulated to avoid confusion among customers

    Trade names of drugs may soon be regulated to avoid confusion among customers

    Health officials believe that many medicines, being sold under the same name in India, put patients' safety at risk

  • Boutique bank Moelis eyes expansion in India amid M&A boom

    Boutique bank Moelis eyes expansion in India amid M&A boom

    Manisha Girotra, who previously headed the Indian unit of Swiss bank UBS and is well known in the industry, said she expects deals in sectors such as financials, telecoms and pharmaceuticals to continue driving M&A activity in the South Asian nation.

  • IT, pharma in focus after Trump's tough talk on pricing

    IT, pharma in focus after Trump's tough talk on pricing

    US president-elect claimed pharmaceutical companies were “getting away with murder” with respect to drug pricing; outsourcing of jobs by US firms will soon be a thing of the past.

  • Pharma cos may report subdued performance in Q2 FY17: Report

    Pharma cos may report subdued performance in Q2 FY17: Report

    Domestic pharmaceutical companies are likely to report subdued sales, EBITDA and PAT figures in the second quarter of this fiscal, even as the formulations business may see a strong recovery, Reliance Securities said in its report.

  • 660 pharma cos have registered with IPDMS till date: Govt

    660 pharma cos have registered with IPDMS till date: Govt

    "As on date, 660 pharmaceutical companies have registered in the Integrated Pharmaceutical Database Management System (IPDMS) and 58,027 product details have been entered," Minister of State for Chemicals and Fertilisers Mansukh Lal Mandaviya said in a written reply to the Rajya Sabha.

  • Bom HC imposes stay order on govt's move to cap drug prices

    Bom HC imposes stay order on govt's move to cap drug prices

    The High Court has said that these companies are unlikely to take any further price cuts over the WPI which would be under the revision of the national list of essential medicines, reports Ekta Batra of CNBC-TV18.

  • FDI up to 74% in brownfield pharma under automatic route

    FDI up to 74% in brownfield pharma under automatic route

    The government on June 20 allowed up to 74 percent foreign direct investment in the existing pharmaceutical companies through automatic route, with an aim to promote the sector

  • Meet with pharma companies, hydel projs on new rules in Sikkim

    Meet with pharma companies, hydel projs on new rules in Sikkim

    Various issues pertaining to waste management and problems faced by the units were discussed at length and the units have agreed to comply with the new Rules, official sources said today.

  • Govt weighs relaxing FDI norms in brownfield pharma cos

    Govt weighs relaxing FDI norms in brownfield pharma cos

    According to a proposal of the Finance Ministry, FDI up to 49 percent should be allowed through the automatic route and anything beyond through approval of the Foreign Investment Promotion Board (FIPB), sources said.

  • 'Pharma firms should halve prices on patented, imported drugs'

    'Pharma firms should halve prices on patented, imported drugs'

    The five drugs are for treatment of cancer or other major diseases, and are very expensive as they are patented or imported, Li Bin head of National Health and Family Planning Commission said today.

  • Tight USFDA scrutiny key challenge for Indian pharma cos: Icra

    Tight USFDA scrutiny key challenge for Indian pharma cos: Icra

    "Greater scrutiny by USFDA is emerging as a key challenge for the (Indian) pharmaceutical sector. New product approvals and margins of pharma companies are at risk but credit profiles are unlikely to be impacted," said the report by rating agency Icra.

  • Dr. Rinky Kapoor Named "Best Dermatologist in India" by Worldwide Achievers, at the Healthcare Excellence Summit 2015

    Dr. Rinky Kapoor Named "Best Dermatologist in India" by Worldwide Achievers, at the Healthcare Excellence Summit 2015

    At the Healthcare Excellence Summit 2015, organized by Worldwide Achievers, Dr. Rinky Kapoor, cosmetic dermatologist and laser skin ...

  • Dr. Debraj Shome Wins the "Best Plastic Surgeon in India" Award at Healthcare Excellence Summit 2015

    Dr. Debraj Shome Wins the "Best Plastic Surgeon in India" Award at Healthcare Excellence Summit 2015

    Adding a new feather in his cap, renowned plastic surgeon, Dr. Debraj Shome of the Esthetic Clinics, Mumbai was named the “Best Plastic Surgeon ...

  • Benefits from oil, govt steps to come with lag: TVF Cap

    Benefits from oil, govt steps to come with lag: TVF Cap

    In the last nine months, the government has taken many right steps to improve the economy, says Shiv Puri, founder and MD of TVF Capital Advisors. It now needs to focus especially on the infrastructure sector in the Budget, he adds.

  • Govt to review FDI policy in pharma sector on Monday

    Govt to review FDI policy in pharma sector on Monday

    "The Cabinet will review the FDI policy in pharmaceutical sector on Monday," an official said. The Department of Industrial Policy and Promotion (DIPP) has proposed to reduce FDI cap from 100 percent to 49 percent in the "rare or critical pharma verticals."

  • Parliament panel suggests ban on FDI in brown field pharma

    Parliament panel suggests ban on FDI in brown field pharma

    A parliamentary committee today suggested a 'blanket ban' on FDI in existing pharmaceutical companies saying the policy in the sensitive sector should be dictated by public good.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347